Dissociated response and clinical benefit in patients treated with nivolumab monotherapy View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-02-10

AUTHORS

Yuki Sato, Takeshi Morimoto, Shigeo Hara, Kazuma Nagata, Kazutaka Hosoya, Atsushi Nakagawa, Ryo Tachikawa, Keisuke Tomii

ABSTRACT

Immune checkpoint inhibitors (ICIs) are effective for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, an unconventional response pattern is sometimes encountered. A dissociated response (DR), characterized by some lesions shrinking and others growing, has been recognized with ICI treatment. In this study, we examined the characteristics and treatment outcomes of DR in previously treated NSCLC patients, receiving nivolumab monotherapy. We conducted a retrospective cohort study of previously treated patients with advanced NSCLC who received nivolumab. We assessed the tumor response of each organ using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at the first radiologic evaluation. We investigated treatment outcome and compared overall survival using the Kaplan-Meier Method and log-rank tests. Further, we conducted the same analysis in patients who had previously received chemotherapy or tyrosine kinase inhibitor therapy in our hospital. Between April 2016 and September 2018, 107 patients who received nivolumab fulfilled the inclusion criteria. Of them, 5 (5%) patients showed a DR. There were no specific differences in characteristics between DR and non-DR cases. Patients showing DR had significantly longer overall survival than those showing concordant progressive disease (46.9 vs. 8.2 months, p = 0.038). The frequencies of DR in the ICI, chemotherapy, and tyrosine kinase inhibitor-treated cohorts were 5%, 1%, and 4%, respectively. DR was uncommon, but this presented a distinctive pattern of nivolumab response. Some patients might benefit from continuing nivolumab therapy and may achieve a longer overall survival. More... »

PAGES

1170-1178

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-021-01077-7

DOI

http://dx.doi.org/10.1007/s10637-021-01077-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1135319652

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33566254


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immune Checkpoint Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nivolumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Response Evaluation Criteria in Solid Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sato", 
        "givenName": "Yuki", 
        "id": "sg:person.01044701724.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044701724.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Epidemiology, Hyogo College of Medicine, 663-8501, Nishinomiya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.272264.7", 
          "name": [
            "Department of Clinical Research Center, Kobe City Medical Center General Hospital, 650-0047, Kobe, Japan", 
            "Department of Clinical Epidemiology, Hyogo College of Medicine, 663-8501, Nishinomiya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morimoto", 
        "givenName": "Takeshi", 
        "id": "sg:person.011273662612.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Pathology, Kobe City Medical Center General Hospital, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Clinical Pathology, Kobe City Medical Center General Hospital, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hara", 
        "givenName": "Shigeo", 
        "id": "sg:person.01311670134.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311670134.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nagata", 
        "givenName": "Kazuma", 
        "id": "sg:person.01300361475.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300361475.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hosoya", 
        "givenName": "Kazutaka", 
        "id": "sg:person.016016734267.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016016734267.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakagawa", 
        "givenName": "Atsushi", 
        "id": "sg:person.011042354025.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011042354025.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tachikawa", 
        "givenName": "Ryo", 
        "id": "sg:person.0655423507.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655423507.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomii", 
        "givenName": "Keisuke", 
        "id": "sg:person.01340443712.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340443712.07"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2021-02-10", 
    "datePublishedReg": "2021-02-10", 
    "description": "Immune checkpoint inhibitors (ICIs) are effective for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, an unconventional response pattern is sometimes encountered. A dissociated response (DR), characterized by some lesions shrinking and others growing, has been recognized with ICI treatment. In this study, we examined the characteristics and treatment outcomes of DR in previously treated NSCLC patients, receiving nivolumab monotherapy. We conducted a retrospective cohort study of previously treated patients with advanced NSCLC who received nivolumab. We assessed the tumor response of each organ using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at the first radiologic evaluation. We investigated treatment outcome and compared overall survival using the Kaplan-Meier Method and log-rank tests. Further, we conducted the same analysis in patients who had previously received chemotherapy or tyrosine kinase inhibitor therapy in our hospital. Between April 2016 and September 2018, 107 patients who received nivolumab fulfilled the inclusion criteria. Of them, 5 (5%) patients showed a DR. There were no specific differences in characteristics between DR and non-DR cases. Patients showing DR had significantly longer overall survival than those showing concordant progressive disease (46.9 vs. 8.2\u00a0months, p\u2009=\u20090.038). The frequencies of DR in the ICI, chemotherapy, and tyrosine kinase inhibitor-treated cohorts were 5%, 1%, and 4%, respectively. DR was uncommon, but this presented a distinctive pattern of nivolumab response. Some patients might benefit from continuing nivolumab therapy and may achieve a longer overall survival.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-021-01077-7", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "keywords": [
      "non-small cell lung cancer", 
      "immune checkpoint inhibitors", 
      "advanced non-small cell lung cancer", 
      "dissociated response", 
      "longer overall survival", 
      "overall survival", 
      "nivolumab monotherapy", 
      "treatment outcomes", 
      "tyrosine kinase inhibitor therapy", 
      "unconventional response patterns", 
      "first radiologic evaluation", 
      "retrospective cohort study", 
      "Solid Tumors criteria", 
      "Response Evaluation Criteria", 
      "Kaplan-Meier method", 
      "cell lung cancer", 
      "log-rank test", 
      "kinase inhibitor therapy", 
      "Tumors criteria", 
      "nivolumab response", 
      "nivolumab therapy", 
      "checkpoint inhibitors", 
      "ICI treatment", 
      "NSCLC patients", 
      "cohort study", 
      "radiologic evaluation", 
      "progressive disease", 
      "inhibitor therapy", 
      "clinical benefit", 
      "lung cancer", 
      "tumor response", 
      "inclusion criteria", 
      "patients", 
      "nivolumab", 
      "monotherapy", 
      "chemotherapy", 
      "survival", 
      "therapy", 
      "outcomes", 
      "response patterns", 
      "response", 
      "distinctive patterns", 
      "specific differences", 
      "hospital", 
      "lesions", 
      "cohort", 
      "cancer", 
      "disease", 
      "criteria", 
      "treatment", 
      "inhibitors", 
      "organs", 
      "study", 
      "evaluation criteria", 
      "same analysis", 
      "patterns", 
      "differences", 
      "evaluation", 
      "cases", 
      "benefits", 
      "test", 
      "characteristics", 
      "frequency", 
      "analysis", 
      "method"
    ], 
    "name": "Dissociated response and clinical benefit in patients treated with nivolumab monotherapy", 
    "pagination": "1170-1178", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1135319652"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-021-01077-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33566254"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-021-01077-7", 
      "https://app.dimensions.ai/details/publication/pub.1135319652"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_918.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-021-01077-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-021-01077-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-021-01077-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-021-01077-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-021-01077-7'


 

This table displays all metadata directly associated to this object as RDF triples.

237 TRIPLES      20 PREDICATES      104 URIs      96 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-021-01077-7 schema:about N062a57facd1046198eb87afc7a454fa1
2 N1628a763f1cc4e95b887b21551a490f6
3 N48747f3ff5574a5aa89339ee48aa6351
4 N4bc57f7b54d64196a1336ef580069ee4
5 N6c5d4842042b4c1dae957be83b64021a
6 N78eed43e8d064b6a8ce50e3ebbabcada
7 N8bceba6cc2bb4f2dbd31f2d4fc5f0bd0
8 N9aa847fcd1d54d2b888a73a5ccaa00df
9 Na4e6a9111b9041f3bc2d00923506bfe2
10 Na6b6355dbd464c3da6c05d77e0d1e826
11 Na79dffb0242c4ba58e10e07fb353b129
12 Na81ea265f5e74e6aba405f91e5dc22c5
13 Na8b9a35c1ccb4df99b6997076a112429
14 Ncb63c788e3ec437d8a80a2ede9101aad
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author N67e7a5dcdbe74f0394cc8d85a6742fb5
18 schema:datePublished 2021-02-10
19 schema:datePublishedReg 2021-02-10
20 schema:description Immune checkpoint inhibitors (ICIs) are effective for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, an unconventional response pattern is sometimes encountered. A dissociated response (DR), characterized by some lesions shrinking and others growing, has been recognized with ICI treatment. In this study, we examined the characteristics and treatment outcomes of DR in previously treated NSCLC patients, receiving nivolumab monotherapy. We conducted a retrospective cohort study of previously treated patients with advanced NSCLC who received nivolumab. We assessed the tumor response of each organ using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at the first radiologic evaluation. We investigated treatment outcome and compared overall survival using the Kaplan-Meier Method and log-rank tests. Further, we conducted the same analysis in patients who had previously received chemotherapy or tyrosine kinase inhibitor therapy in our hospital. Between April 2016 and September 2018, 107 patients who received nivolumab fulfilled the inclusion criteria. Of them, 5 (5%) patients showed a DR. There were no specific differences in characteristics between DR and non-DR cases. Patients showing DR had significantly longer overall survival than those showing concordant progressive disease (46.9 vs. 8.2 months, p = 0.038). The frequencies of DR in the ICI, chemotherapy, and tyrosine kinase inhibitor-treated cohorts were 5%, 1%, and 4%, respectively. DR was uncommon, but this presented a distinctive pattern of nivolumab response. Some patients might benefit from continuing nivolumab therapy and may achieve a longer overall survival.
21 schema:genre article
22 schema:isAccessibleForFree true
23 schema:isPartOf N2ba28ba445de4a5fb009283d22e02749
24 N75fb91f6640147538ba9c527f9b61588
25 sg:journal.1094201
26 schema:keywords ICI treatment
27 Kaplan-Meier method
28 NSCLC patients
29 Response Evaluation Criteria
30 Solid Tumors criteria
31 Tumors criteria
32 advanced non-small cell lung cancer
33 analysis
34 benefits
35 cancer
36 cases
37 cell lung cancer
38 characteristics
39 checkpoint inhibitors
40 chemotherapy
41 clinical benefit
42 cohort
43 cohort study
44 criteria
45 differences
46 disease
47 dissociated response
48 distinctive patterns
49 evaluation
50 evaluation criteria
51 first radiologic evaluation
52 frequency
53 hospital
54 immune checkpoint inhibitors
55 inclusion criteria
56 inhibitor therapy
57 inhibitors
58 kinase inhibitor therapy
59 lesions
60 log-rank test
61 longer overall survival
62 lung cancer
63 method
64 monotherapy
65 nivolumab
66 nivolumab monotherapy
67 nivolumab response
68 nivolumab therapy
69 non-small cell lung cancer
70 organs
71 outcomes
72 overall survival
73 patients
74 patterns
75 progressive disease
76 radiologic evaluation
77 response
78 response patterns
79 retrospective cohort study
80 same analysis
81 specific differences
82 study
83 survival
84 test
85 therapy
86 treatment
87 treatment outcomes
88 tumor response
89 tyrosine kinase inhibitor therapy
90 unconventional response patterns
91 schema:name Dissociated response and clinical benefit in patients treated with nivolumab monotherapy
92 schema:pagination 1170-1178
93 schema:productId N334a36194c694351ac8f67bac4b3ae37
94 N617ca194989a4cb48218fd1ea3bdc31a
95 Nd3dab52bf67e4d1da50d303f2d38945b
96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1135319652
97 https://doi.org/10.1007/s10637-021-01077-7
98 schema:sdDatePublished 2022-09-02T16:07
99 schema:sdLicense https://scigraph.springernature.com/explorer/license/
100 schema:sdPublisher N4591621e75cb4fb6878c5bb811ef74cf
101 schema:url https://doi.org/10.1007/s10637-021-01077-7
102 sgo:license sg:explorer/license/
103 sgo:sdDataset articles
104 rdf:type schema:ScholarlyArticle
105 N062a57facd1046198eb87afc7a454fa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Response Evaluation Criteria in Solid Tumors
107 rdf:type schema:DefinedTerm
108 N1628a763f1cc4e95b887b21551a490f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Aged
110 rdf:type schema:DefinedTerm
111 N2b52609103f7457a9ebb7e065cf07e7d rdf:first sg:person.0655423507.20
112 rdf:rest Ne880e1c7214243a49b4f656d75a98dca
113 N2ba28ba445de4a5fb009283d22e02749 schema:volumeNumber 39
114 rdf:type schema:PublicationVolume
115 N334a36194c694351ac8f67bac4b3ae37 schema:name doi
116 schema:value 10.1007/s10637-021-01077-7
117 rdf:type schema:PropertyValue
118 N4591621e75cb4fb6878c5bb811ef74cf schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 N48747f3ff5574a5aa89339ee48aa6351 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Carcinoma, Non-Small-Cell Lung
122 rdf:type schema:DefinedTerm
123 N4bc57f7b54d64196a1336ef580069ee4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Survival Rate
125 rdf:type schema:DefinedTerm
126 N617ca194989a4cb48218fd1ea3bdc31a schema:name dimensions_id
127 schema:value pub.1135319652
128 rdf:type schema:PropertyValue
129 N67e7a5dcdbe74f0394cc8d85a6742fb5 rdf:first sg:person.01044701724.61
130 rdf:rest Nbb2af5ef44974fc3806f7c7de230e828
131 N6c5d4842042b4c1dae957be83b64021a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Male
133 rdf:type schema:DefinedTerm
134 N71df92a2b9404e68a5ae6b17919374e0 rdf:first sg:person.011042354025.34
135 rdf:rest N2b52609103f7457a9ebb7e065cf07e7d
136 N75fb91f6640147538ba9c527f9b61588 schema:issueNumber 4
137 rdf:type schema:PublicationIssue
138 N78eed43e8d064b6a8ce50e3ebbabcada schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Middle Aged
140 rdf:type schema:DefinedTerm
141 N85105a154c5d4b32a1cba7ccfcd1f221 rdf:first sg:person.01300361475.63
142 rdf:rest Na0ff8ef59b144e0aa04a6cbf362cd65b
143 N8bceba6cc2bb4f2dbd31f2d4fc5f0bd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 N9aa847fcd1d54d2b888a73a5ccaa00df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Retrospective Studies
148 rdf:type schema:DefinedTerm
149 Na0ff8ef59b144e0aa04a6cbf362cd65b rdf:first sg:person.016016734267.92
150 rdf:rest N71df92a2b9404e68a5ae6b17919374e0
151 Na4e6a9111b9041f3bc2d00923506bfe2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Immune Checkpoint Inhibitors
153 rdf:type schema:DefinedTerm
154 Na6b6355dbd464c3da6c05d77e0d1e826 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Nivolumab
156 rdf:type schema:DefinedTerm
157 Na79dffb0242c4ba58e10e07fb353b129 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Treatment Outcome
159 rdf:type schema:DefinedTerm
160 Na81ea265f5e74e6aba405f91e5dc22c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Female
162 rdf:type schema:DefinedTerm
163 Na8b9a35c1ccb4df99b6997076a112429 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Lung Neoplasms
165 rdf:type schema:DefinedTerm
166 Nbb2af5ef44974fc3806f7c7de230e828 rdf:first sg:person.011273662612.03
167 rdf:rest Ne59b8ee99680467c88573f48d2ccdf1d
168 Ncb63c788e3ec437d8a80a2ede9101aad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Cohort Studies
170 rdf:type schema:DefinedTerm
171 Nd3dab52bf67e4d1da50d303f2d38945b schema:name pubmed_id
172 schema:value 33566254
173 rdf:type schema:PropertyValue
174 Ne59b8ee99680467c88573f48d2ccdf1d rdf:first sg:person.01311670134.98
175 rdf:rest N85105a154c5d4b32a1cba7ccfcd1f221
176 Ne880e1c7214243a49b4f656d75a98dca rdf:first sg:person.01340443712.07
177 rdf:rest rdf:nil
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
182 schema:name Oncology and Carcinogenesis
183 rdf:type schema:DefinedTerm
184 sg:journal.1094201 schema:issn 0167-6997
185 1573-0646
186 schema:name Investigational New Drugs
187 schema:publisher Springer Nature
188 rdf:type schema:Periodical
189 sg:person.01044701724.61 schema:affiliation grid-institutes:grid.410843.a
190 schema:familyName Sato
191 schema:givenName Yuki
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044701724.61
193 rdf:type schema:Person
194 sg:person.011042354025.34 schema:affiliation grid-institutes:grid.410843.a
195 schema:familyName Nakagawa
196 schema:givenName Atsushi
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011042354025.34
198 rdf:type schema:Person
199 sg:person.011273662612.03 schema:affiliation grid-institutes:grid.272264.7
200 schema:familyName Morimoto
201 schema:givenName Takeshi
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03
203 rdf:type schema:Person
204 sg:person.01300361475.63 schema:affiliation grid-institutes:grid.410843.a
205 schema:familyName Nagata
206 schema:givenName Kazuma
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300361475.63
208 rdf:type schema:Person
209 sg:person.01311670134.98 schema:affiliation grid-institutes:grid.410843.a
210 schema:familyName Hara
211 schema:givenName Shigeo
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311670134.98
213 rdf:type schema:Person
214 sg:person.01340443712.07 schema:affiliation grid-institutes:grid.410843.a
215 schema:familyName Tomii
216 schema:givenName Keisuke
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340443712.07
218 rdf:type schema:Person
219 sg:person.016016734267.92 schema:affiliation grid-institutes:grid.410843.a
220 schema:familyName Hosoya
221 schema:givenName Kazutaka
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016016734267.92
223 rdf:type schema:Person
224 sg:person.0655423507.20 schema:affiliation grid-institutes:grid.410843.a
225 schema:familyName Tachikawa
226 schema:givenName Ryo
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655423507.20
228 rdf:type schema:Person
229 grid-institutes:grid.272264.7 schema:alternateName Department of Clinical Epidemiology, Hyogo College of Medicine, 663-8501, Nishinomiya, Japan
230 schema:name Department of Clinical Epidemiology, Hyogo College of Medicine, 663-8501, Nishinomiya, Japan
231 Department of Clinical Research Center, Kobe City Medical Center General Hospital, 650-0047, Kobe, Japan
232 rdf:type schema:Organization
233 grid-institutes:grid.410843.a schema:alternateName Department of Clinical Pathology, Kobe City Medical Center General Hospital, 650-0047, Kobe, Japan
234 Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan
235 schema:name Department of Clinical Pathology, Kobe City Medical Center General Hospital, 650-0047, Kobe, Japan
236 Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan
237 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...